Fig. 3

NOD1/RIP2 inhibition alleviated ICH-induced brain damage and microglial activation. a, b Levels of injury volume, brain water content and neurological function in the indicated group (n = 6 mice/group for analysis of injury volume and brain water content; n = 10 mice/group for analysis of neurological function. #P < 0.01 vs. the DMSO-treated group). c, d CD68-, Iba-1-positive cells and the cell body size of microglia in the perihematomal tissue by immunofluorescence staining (n = 6 mice for each group, 3 images/mouse; *P < 0.01 vs. the sham group, #P < 0.01 vs. the DMSO-treated group). e The representative images of the four subtypes of microglia: type 1, the resting form of microglia; type 2, the initiated form of activated microglia; type 3, the activated form of microglia with non-phagocytic function; type 4, the overactivated form of microglia with phagocytic function. f, g Immunohistochemical analysis of microglial subtypes and quantitative data of activated microglia in the indicated groups (n = 6 mice for each group, 3 images/mouse; *P < 0.01 vs. the sham group, #P < 0.01 vs. the DMSO-treated group). All data are representative of at least six independent experiments